Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 140.3% in November

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 291,500 shares, an increase of 140.3% from the October 31st total of 121,300 shares. Based on an average trading volume of 266,300 shares, the short-interest ratio is currently 1.1 days. Approximately 11.5% of the company's stock are sold short.

Aligos Therapeutics Stock Up 7.7 %

Shares of ALGS traded up $1.64 during midday trading on Thursday, reaching $22.99. 277,105 shares of the stock were exchanged, compared to its average volume of 87,747. The company has a market cap of $82.49 million, a price-to-earnings ratio of -1.73 and a beta of 2.11. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $30.00. The firm has a 50 day simple moving average of $11.50 and a 200-day simple moving average of $12.61.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The business had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the previous year, the business posted ($10.25) EPS. Research analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Armistice Capital LLC increased its position in Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company's stock worth $2,540,000 after buying an additional 363,000 shares during the last quarter. Opaleye Management Inc. increased its holdings in shares of Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company's stock valued at $1,597,000 after acquiring an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Aligos Therapeutics by 26.1% during the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company's stock valued at $289,000 after acquiring an additional 171,490 shares during the last quarter. Institutional investors own 60.43% of the company's stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).